Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)

被引：0
|
作者：
Mainwaring, Paul [1 ]
Tannir, Nizar M. [1 ]
Powles, Thomas [1 ]
Motzer, Robert J. [1 ]
Rolland, Frederic [1 ]
Gravis, Gwanaelle [1 ]
Staehler, Michael [1 ]
Rink, Michael [1 ]
Retz, Margitta [1 ]
Csoszi, Tibor [1 ]
McCaffrey, John A. [1 ]
De Giorgi, Ugo [1 ]
Caserta, Claudia [1 ]
Cheporov, Sergey [1 ]
Gonzalez, Emilio Esteban [1 ]
Duran, Ignacio [1 ]
Larkin, James G. [1 ]
Berg, William [1 ]
Clary, Douglas O. [1 ]
Escudier, Bernard [1 ]
Choueiri, Toni K. [1 ]
机构：
[1] Mater Med Ctr, ICON Canc Care, South Brisbane, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
183
引用
收藏
页码：129 / 130
页数：2
相关论文
共 50 条
  • [1] Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tannir, N.
    Powles, T.
    Motzer, R. J.
    Rolland, F.
    Gravis, G.
    Staehler, M.
    Rink, M.
    Retz, M.
    Csoszi, T.
    McCaffrey, J.
    De Giorgi, U.
    Caserta, C.
    Cheporov, S.
    Esteban Gonzalez, E.
    Duran, I.
    Larkin, J. G.
    Berg, W.
    Clary, D.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Grullich, Carsten
    Nott, Louise M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
    Duran, Ignacio
    Maroto, Pablo
    Suarez, Cristina
    Castellano, Daniel E.
    Garcia del Muro, Xavier
    Costa, Luis
    Martin-Couce, Lidia
    Benzaghou, Fawzi
    Thomas, Stephane
    Markby, David W.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve in patients (pts) with advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Mainwaring, Paul
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Griillich, Carsten
    Nott, Louise M.
    Cuff, Katharine Ellen
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard J.
    Pal, Sumanta K.
    Powles, Thomas
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)
    Bergmann, L.
    Donskov, F.
    Motzer, R. J.
    Voog, E.
    Hovey, E. J.
    Gruellich, C.
    Nott, L. M.
    Cuff, K. E.
    Gil, T.
    Jensen, N., V
    Chevreau, C.
    Negrier, S.
    Depenbusch, R.
    Cornelio, I
    Champsaur, A.
    Escudier, B. J.
    Pal, S. K.
    Powles, T.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 201
  • [7] Analysis of overall survival (OS) based on early tumour shrinkage in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tan, T. H.
    Duran, I.
    Maroto, P.
    Suarez, C.
    Castellano, D.
    Garcia del Muro, X.
    Costa, L.
    Martin-Couce, L.
    Benzaghou, F.
    Thomas, S.
    Markby, D. W.
    Choueiri, T. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 186 - 186
  • [8] Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).
    Pal, Sumanta K.
    Motzer, Robert J.
    Fishman, Mayer N.
    McDermott, Raymond S.
    Passos-Coelho, Jose
    Kopyltsov, Evgeniy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 109 - 109
  • [10] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard J.
    Donskov, Frede
    Grunwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoffski, Patrick
    Szczylik, Cezary
    Peltola, Katriina Johanna
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas O.
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345